GlassScriptPhysician profile
Robert G Haddad
NPI 1760487904
$4,539.35
in general payments reported to CMS, 2019-2025
42 companies · $1,532 in 2025
The $1,532 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.04 · 2020: $134 · 2021: $164 · 2022: $104 · 2023: $1,300 · 2024: $1,240 · 2025: $1,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,072.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.57 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $642.33 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $452.78 | 2019-2025 | |
| Novo Nordisk INC | $380.39 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $300.51 | 2019-2025 | |
| Dexcom, INC. | $217.97 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Amgen INC. | $184.81 | 2023-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $150.83 | 2024-2025 | |
| Astellas Pharma US INC | $139.42 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $116.42 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Daiichi Sankyo INC. | $104.98 | 2022-2025 | Injectafer |
| Lilly USA, LLC | $98.34 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $98.00 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $97.72 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.27 | 2023-2025 | Jardiance |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.